Part A of the multi-arm phase Ib TATTON study (NCT02143466) demonstrated the safety and tolerability of osimertinib plus savolitinib (n = 18) in patients with advanced NSCLC disease progression on a prior EGFR–TKI [44]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.